Compare Msci Inc (MSCI) vs Sanofi SA (SNY) Price & Performance

Msci IncTrade

Sanofi SATrade

Price performance (Past 24H)

Key statistics

Msci Inc vs Sanofi SA — how do they compare? Msci Inc trades at $562.94 (market cap $45.51B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.3× Msci Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.

	MSCI	SNY
Market Cap	$45.51B	$104.83B
Sector	Financials	Health
52-Week High	$643.83	$52.34
52-Week Low	$511.84	$41.33
Enterprise Value	$51.67B	$121.32B
Dividend Yield	1.31%	5.5%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSCI

MSCI posts solid Q2 results but misses revenue and EPS targets, shares fall.Seeking Alpha · 8 hours agoNeutral S&P DJI and MSCI launch consultation on potential updates to GICS industry classification system.PRNewsWire · 4 days agoNeutral View details →

SNY

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026GlobeNewsWire · 9 hours agoNeutral View details →

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.